| Name | Title | Contact Details |
|---|
With 20+ years of collective experience, OeP helps brands capitalize on Amazons growth, using data-driven strategies executed by experts, enabled by technology, and aligned with Amazons dynamic platform and KPIs.
Veterinary United is a Michigan-based company that operates a network of 22 veterinary hospitals, boarding, and daycare centers primarily in Southeastern Michigan. Founded 27 years ago by Dr. Thomas Bankstahl and his wife Julie, the company has grown to employ approximately 276 people and generate annual revenues of around $40.5 million. Its mission is to empower veterinary practices to provide exceptional care through comprehensive support and resources. The company offers full veterinary healthcare services, including medical care, boarding, and daycare for pets. Veterinary United enhances its practices with advanced technology, such as a unified, cloud-based practice management system, which streamlines operations and improves client and patient experiences. Additionally, it provides extensive business support services, including IT, marketing, and professional development, allowing practices to focus on clinical care while promoting sustainable growth. Veterinary United fosters a supportive work culture that emphasizes career development and work-life balance. New veterinary graduates receive tailored mentorship, and all employees enjoy competitive salaries and benefits. The company is dedicated to delivering high-quality pet care while supporting its network of hospitals and veterinary professionals.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.